LGR5 inhibitors (Peking University Cancer Hospital)

N/A

Report date: 2025/06/11 11:17:06
NME

Base Information

Drug NameLGR5 inhibitors (Peking University Cancer Hospital)
Drug Alias Nameleucine-rich repeat containing G protein receptor 5 (Peking University Cancer Hospital)LN-35690555LN-35663290
ClassificationSmall molecules
Mechanisms of ActionLeucine-rich repeat-containing G-protein coupled receptor 5 antagonists
TargetsLeucine-rich repeat-containing G-protein coupled receptor 5
Therapy Area/IndicationsStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBeijing Cancer Hospital
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Cancer Hospital
Inactive CompaniesN/A
Active IndicationsStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A